SCHEMBL769799

SCHEMBL769799

CC[C@H]1O[C@@H](OC)[C@H](OCc2ccccc2)[C@H](F)[C@@H]1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR1 P30872 1/20 0.47
SSTR2 P30874 1/20 0.47
SSTR4 P31391 1/20 0.47
SSTR3 P32745 1/20 0.47
SSTR5 P35346 1/20 0.47
BCHE P06276 1/20 0.45
PTPN2 P17706 2/20 0.38
PTPN1 P18031 2/20 0.38
GJB2 P29033 1/20 0.37
LGALS8 O00214 1/20 0.37
SLC6A2 P23975 1/20 0.35
FGF1 P05230 2/20 0.35
FGF2 P09038 2/20 0.35
VEGFA P15692 2/20 0.35
HPSE Q9Y251 2/20 0.35
TACR2 P21452 1/20 0.34
PDPK1 O15530 1/20 0.34
MTOR P42345 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11921409 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15871629 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL2621331 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL15502120 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL412334 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL14999636 0.89 SSTR5 (0.51) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL14370515 0.88 SSTR1 (0.53) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL17174992 0.88 SSTR5 (0.50) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL16367561 0.88 SSTR5 (0.50) SSTR1SSTR2SSTR4SSTR3SSTR5
SCHEMBL26879259 0.87 SSTR5 (0.49) SSTR1SSTR2SSTR4SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9005906-B2 Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2015-04-14 US disclosed
US-20140315979-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2014-10-23 US disclosed
US-8796437-B2 Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2014-08-05 US disclosed
US-20130211064-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2013-08-15 US disclosed
US-8440803-B2 Tetrahydropyran nucleic acid analogs ISIS PHARMACEUTICALS, INC. (US) 2013-05-14 US disclosed
US-20120071645-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS ISIS PHARMACEUTICALS, INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071645-A1 TETRAHYDROPYRAN NUCLEIC ACID ANALOGS HNRNPM, POLM, RNMT SSTR1 4835/4885SSTR2 4794/4885SSTR4 4819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.